Welcome to our dedicated page for Bioventus SEC filings (Ticker: BVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bioventus Inc. filings document the formal disclosures of a Nasdaq-listed medical device company with Class A common stock registered under the Exchange Act. Recent Form 8-K reports furnish operating results and financial condition updates, including quarterly and annual earnings releases for the company’s active-healing product portfolio.
The company’s regulatory filings also cover proxy governance for annual stockholder meetings, board composition matters, emerging growth company status, credit arrangements entered into by Bioventus LLC and its subsidiaries, and product regulatory events such as FDA 510(k) clearance for TalisMann and StimTrial within the Peripheral Nerve Stimulation portfolio.
Bioventus Inc. director William A. Hawkins reported equity compensation activity involving restricted stock units (RSUs) and Class A common stock. On June 3, 2026, he received a grant of 30,994 RSUs, each representing a contingent right to receive one share of Class A common stock, with vesting tied to continued board service.
On June 2, 2026, 39,789 RSUs vested and were exercised into 39,789 shares of Class A common stock. Following these transactions, Hawkins directly owned 297,640 shares of Class A common stock and held 30,994 RSUs as a separate derivative position, reflecting routine director compensation and vesting rather than open-market trading.
Bioventus Inc. director Philip G. Cowdy reported equity compensation changes. He received a grant of 25,146 restricted stock units (RSUs), each representing one share of Class A common stock, which will vest based on continued board service. A separate RSU award for 32,282 units vested and was exercised into 32,282 shares of Class A common stock, leaving him with 43,982 common shares directly held and 25,146 RSUs outstanding. These transactions reflect compensation awards and option-like exercises rather than open-market buying or selling.
Bioventus Inc. director Pat Beyer reported equity compensation activity and an option-like vesting event. On June 3, 2026, Beyer received a grant of 25,146 restricted stock units, each representing a contingent right to one share of Class A common stock. These RSUs will vest on the earlier of the day immediately preceding the issuer's first annual meeting of stockholders following the grant date or the first anniversary of the grant, subject to continued board service.
On June 2, 2026, previously granted RSUs vested and were exercised into 32,282 shares of Class A common stock, eliminating that RSU balance. Following these transactions, Beyer holds 108,718 shares of Class A common stock directly and 25,146 RSUs that remain outstanding.
Bioventus Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A total of 75,279,174 shares of Class A and Class B common stock were present in person or by proxy, representing approximately 90.23% of outstanding shares entitled to vote as of the April 6, 2026 record date.
Stockholders elected all nominated directors to the Board to serve until the 2027 annual meeting and until their successors are elected and qualified, or earlier death, resignation or removal. The filing lists individual vote totals and broker non-votes for each director.
Stockholders also ratified the appointment of Grant Thornton LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,228,481 shares voting for, 5,021 against and 45,672 abstaining, and no broker non-votes reported on this item.
Bioventus Inc. reports U.S. regulatory and reimbursement changes affecting its Exogen Ultrasound Bone Healing System but keeps its 2026 outlook unchanged. The FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including Exogen, from higher-risk Class III to Class II devices.
Following this, CMS updated billing requirements and the Medicare fee schedule for non-invasive bone growth stimulators billed under HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026. Bioventus currently does not expect the revised reimbursement rates for Exogen to have a material impact on fiscal 2026 results and is reiterating its financial guidance, while continuing to evaluate potential longer-term effects of any current or future CMS actions.
Bioventus Inc. reported stronger quarterly results, returning to profitability. Net sales rose to $132.1 million, up 6.6% year over year, driven by growth in Pain Treatments and Surgical Solutions in both U.S. and international markets.
The company generated net income of $3.9 million versus a $3.3 million loss a year ago, with diluted EPS of $0.04. Gross margin improved to 68.7%, and Adjusted EBITDA increased to $23.9 million from $19.2 million.
Operating cash flow improved to $8.9 million, enabling a discretionary $22.0 million prepayment on the 2025 Term Loan. The term loan balance was $274.3 million before discounts, and cash and cash equivalents were $35.8 million. The company remained in compliance with its credit covenants.
Bioventus Inc. reported stronger first-quarter 2026 results, with revenue of $132.1 million, up 6.6% year over year, driven by growth across Pain Treatments, Surgical Solutions and Restorative Therapies.
Net income attributable to Bioventus was $3.1 million, reversing a $2.6 million loss a year earlier, and GAAP diluted EPS improved to $0.04 from a $0.04 loss. Non-GAAP diluted EPS rose to $0.15 from $0.08, supported by higher gross profit, lower interest expense and a 24% increase in Adjusted EBITDA to $23.9 million.
Cash from operations was $8.9 million, compared with a $19.3 million outflow in the prior-year quarter. The company made a $22.0 million discretionary term-loan prepayment and raised full-year 2026 guidance for Adjusted EPS to $0.75–$0.79 and cash from operations to $84–$89 million, while reaffirming net sales guidance of $600–$610 million, implying approximately 6%–7% growth.
Bioventus files a comprehensive annual report describing its business, product portfolio, regulatory environment and principal risks. The company reports U.S. and International segments representing 88% and 12% of net sales for the year ended December 31, 2025, and lists core areas: Pain Treatments, Surgical Solutions and Restorative Therapies. The filing notes FDA 510(k) clearances for TalisMann and StimTrial in July 2025 and a limited commercial release in Q3 2025, followed by a broader launch in early 2026. It discloses intellectual property counts, manufacturing and supply constraints, key regulatory frameworks (U.S. FDA, EU MDR), material legal and reimbursement risks, and that the company had approximately 930 employees as of December 31, 2025.
Bioventus Inc. is asking stockholders to vote at its 2026 virtual Annual Meeting on June 3, 2026 at 10:00 a.m. Eastern Time. Holders of 67,638,295 shares of Class A and 15,786,737 shares of Class B common stock as of April 6, 2026 may vote, with each share receiving one vote.
Stockholders will elect twelve directors to one-year terms and vote on ratifying Grant Thornton LLP as independent auditor for 2026. The proxy details board and committee composition, director independence, governance policies, a Dodd-Frank–aligned compensation clawback, and sizeable equity incentive and employee stock purchase plans supporting long-term equity-based compensation.
Cowdy Philip G. reported acquisition or exercise transactions in this Form 4 filing.
Bioventus Inc. filed an amended insider report for director Philip G. Cowdy to correct a previously reported grant of 2,700 Restricted Stock Units dated April 1, 2021. A footnote explains the earlier Form 4 was filed inadvertently for RSUs that were not accepted, and that as of April 1, 2021, Cowdy held no non-derivative or derivative securities of Bioventus.